8,300 Shares in Insmed, Inc. $INSM Bought by S&CO Inc.

S&CO Inc. purchased a new stake in Insmed, Inc. (NASDAQ:INSM) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 8,300 shares of the biopharmaceutical company’s stock, valued at approximately $835,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. raised its stake in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares during the last quarter. ORG Partners LLC grew its holdings in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank purchased a new position in Insmed during the second quarter valued at approximately $28,000. FNY Investment Advisers LLC purchased a new position in Insmed during the second quarter valued at approximately $33,000. Finally, LRI Investments LLC acquired a new position in Insmed in the second quarter valued at approximately $59,000.

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 179,787 shares of company stock valued at $26,428,149. 3.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

INSM has been the topic of a number of analyst reports. Bank of America raised their price objective on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. UBS Group raised their price target on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Stifel Nicolaus upped their price objective on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. TD Cowen increased their target price on shares of Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Finally, William Blair started coverage on Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating for the company. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.29.

Insmed Stock Performance

INSM opened at $189.70 on Monday. The firm’s fifty day simple moving average is $157.32 and its two-hundred day simple moving average is $116.72. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $197.08. The company has a market cap of $40.46 billion, a price-to-earnings ratio of -33.22 and a beta of 1.05. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. Equities analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.